PrecisionCHD™, Cardio Diagnostics’ flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional ...

A recent publication in JACC: Advances shows a previously unrecognized link between cardiac disease and cancer. The research focused on cardiac biomarkers, which are biological molecules that can ...

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in patients with heart failure with preserved ejection fraction. Heart failure ...

Preeclampsia is a serious multisystem disorder that typically manifests as hypertension and proteinuria after 20 weeks’ gestation. The condition is multifactorial and involves placental, immunological ...

Cancer and heart disease, two leading causes of death worldwide, may be more connected than we previously thought, according to a new UCLA Health study revealing that certain cardiac blood markers can ...

Please provide your email address to receive an email when new articles are posted on . Elevated levels of cardiac biomarkers were indicative of future cancer risk. The association between biomarkers ...

A blood biomarker yet to be used in cardiac arrest care can give a clearer picture of the extent of brain damage after a cardiac arrest. This has been shown in a large international multicentre study ...

Cardiovascular diseases remain the leading cause of death worldwide, accounting for nearly 20 million deaths each year. Rapid diagnosis and risk assessment of cardiac injury are therefore essential ...

Findings from a new study have identified a new model for predicting outcomes for hypertrophic cardiomyopathy (HCM), a heart condition with a prevalence of one in 500 people and a frequent cause of ...

Patients hospitalized for influenza are just as likely as those admitted for COVID-19 to have signs of myocardial involvement, according to a study out Ontario, Canada. Though patients with COVID-19 ...

Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week. The San Diego-based biotech has been evaluating the oral NLRP3 ...